Study S000939

Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)

ClinicalTrials.gov record

Registration

Registration: NCT06517212
Acronym: TRIM-EBC
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 48
Start: 2024-11-26
Primary completion: 2029-08-31
Lead sponsor: Baylor Research Institute
Conditions: Breast Cancer; Breast Neoplasms; Breast Cancers
Interventions: DRUG:Tirzepatide
Results posted: FALSE

Registered primary outcomes

ctDNA efficacy [2 years]
distant disease-free survival efficacy [2 years]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0032441	Evaluating Tirzepatide's Therapeutic Potential in Mitigating Obesity-Associated Comorbidities Kahook, Zaneh, NSUWorks (Nova Southeastern University)	2024	Other trial		cites ClinicalTrials.gov:NCT06517212